VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | BCMA/CD38 CAR-T for R/R MM: promising trial results

Heng Mei, MD, Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, discusses the first-in-human clinical trial (ChiCTR1800018143) of a bispecific CAR T-cell therapy targeting BCMA and CD38 in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Mei highlights the promising results of the trial, in particular improved efficacy and manageable toxicities. The initial data provide strong evidence to support the further development of the dual-target CAR-T for R/R MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter